Fluidigm (NASDAQ:FLDM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “

FLDM traded up $0.40 during trading on Monday, reaching $4.10. The company had a trading volume of 2,393,156 shares, compared to its average volume of 1,411,137. The firm’s 50-day simple moving average is $4.21 and its 200 day simple moving average is $3.37. The company has a market cap of $261.61 million, a price-to-earnings ratio of -5.12 and a beta of 2.02. Fluidigm has a 12-month low of $1.17 and a 12-month high of $12.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.87 and a current ratio of 2.33.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09). The company had revenue of $27.62 million during the quarter. Fluidigm had a negative return on equity of 23.20% and a negative net margin of 48.20%. On average, sell-side analysts expect that Fluidigm will post -0.53 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Swiss National Bank grew its stake in Fluidigm by 5.1% during the 1st quarter. Swiss National Bank now owns 134,900 shares of the medical research company’s stock valued at $343,000 after acquiring an additional 6,600 shares in the last quarter. Citigroup Inc. grew its stake in Fluidigm by 131.7% during the 4th quarter. Citigroup Inc. now owns 14,243 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 8,095 shares in the last quarter. Wells Fargo & Company MN grew its stake in Fluidigm by 7.6% during the 1st quarter. Wells Fargo & Company MN now owns 127,922 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 9,043 shares in the last quarter. Callan Capital LLC purchased a new position in Fluidigm during the 1st quarter valued at about $25,000. Finally, Parallel Advisors LLC purchased a new position in Fluidigm during the 1st quarter valued at about $26,000. 89.79% of the stock is currently owned by institutional investors.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Article: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on Fluidigm (FLDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.